Soft Tissue Sarcoma Pipeline, FDA Approvals, Unmet Needs, Preclinical And Discovery Stage Product, And Companies 2024 (Updated) menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
The China National Intellectual Property Administration CNIPA announced Top 10 Patent Reexamination Invalidation Cases Released in 2021. Invalidation cases cover utility models, invention patents, designs, layout designs of integrated circuits.
Honghui Hu of Wanhuida Intellectual Property considers the impact of the structure-activity relationship on the inventiveness assessment of pharmaceutical compounds
Share this article
Share this article
ResearchAndMarkets.com s offering.
Iodixanol is a third-generation contrast agent that has good solubility and is isotonic to plasma. It is used for cardiovascular angiography, cerebrovascular angiography, abdominal angiography, and so on. Iodixanol was developed by Nycomed, a Norwegian company, naming VISIPAQUE (Nycomed was acquired by GE after the merge with Amersham, and become GE Healthcare).
In 2001, Iodixanol entered the Chinese market. Currently, besides GE Healthcare, the other main manufacturers in China are Jiangsu Hengrui Medicine, Yangtze River Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, and Beijing Beilu Pharmaceutical.
According to this market research, sales value of Iodixanol in the Chinese market has increased from 2016 to 2020. The sales value of Iodixanol in China reached approximately CNY1.49 billion in 2020, with an increase of 1.52% YoY.